Treatment Options. Suresh Pola, MD Kaiser San Diego

Size: px
Start display at page:

Download "Treatment Options. Suresh Pola, MD Kaiser San Diego"

Transcription

1 Treatment Options Suresh Pola, MD Kaiser San Diego

2 Overview of Treatments! Medications! Diet! Complementary and Alternative Medicines! How to treat Pain

3 Treatment Goals and Target! Goals of Treatment should be defined by you and by your provider- together! Common goals:! control of symptoms, controlling inflammation, preventing unnecessary surgeries, minimizing use of steroids, avoiding hospitalizations, avoiding transfusions, minimizing side effects, staying cancer free, and having a good quality of life! Controlling inflammation can reduce risk of colon cancer! Come up with a treatment target

4 Treatment Tips! Quit smoking (could be more effective than other treatments for Crohn s disease!)! Know your medications, doses, and keep track of side effects! If you are not taking your medication, be honest with your provider so that you can come up with a mutual plan that you agree upon and that works! Take your medications as prescribed, set reminders if needed

5 Know the benefits and risks of medications Improves quality of life Treats diarrhea Treats pain Improves nutrition Prevents complications Prevents hospital stay Prevents surgery Prevents cancer Costs Side effects Infection Worsening symptoms Pancreatitis Cancer Unknowns

6 FDA Approved Medications! 5-ASA! Sulfasalazine! Mesalamines! Corticosteroids! Prednisone! Budesonide, Bud MMX! Immunomodulators! Methotrexate! 6MP and azathioprine! Anti-TNF! Infliximab! Adalimumab! Certolizumab! Anti Integrin! Natalizumab! Vedolizumab

7 5-Aminosalicylates (5ASAs)! oral or rectal (enema, suppository)! Exact mechanism unknown- Anti- inflammatory properties! Distant cousin to aspirin (but allergy doesn t cross react)! Approved for Mild to Moderate IBD! 2/3 of patients with UC respond to these medications! A minority of patients with Crohn s are sufficiently controlled on these medications

8 5-Aminosalicylates (5ASAs)! Examples: Rowasa, Canasa, Lialda, mesalamine, Asacol, Delzicol, Sulfasalazine, Colazal, Pentasa, Apriso! Site of action: Colon. (Pentasa: small intestine and colon)! Side effects (not including sulfasalazine): headache, rash, alopecia, interstitial nephritis, pericarditis, pneumonitis, hepatitis, pancreatitis, worsening diarrhea and abdominal pain! Tips:! With the exception of sulfasalazine, oral 5ASA medications can be taken once daily! These are some of our safest medications for IBD!

9 Corticosteroids! Intravenous (typically in hospital)! Oral: Prednisone, Budesonide (Entocort), Budesonide MMX (Uceris)! Suppository and Enema formulations

10 ! Tip: Prednisone is a good short term bridge to a long term less side effect prone treatment approach. Always have a schedule to be tapered off! Corticosteroids! Mechanism of action: blocks inflammation including inflammatory mediators (cytokines)! Site of action:! Systemic: prednisone or IV steroid,! Topical: Budesonide: terminal ileum and right colon- Crohn s, Budesonide MMX: colon- UC,! Side effects: bruising, infection, elevation in blood pressure, behavioral changes, stretch marks, weight gain, insomnia, long term use has been associated with higher rates of death, osteoporosis, cataracts, osteonecrosis! These are uncommon in low dose budesonide formulations

11 Thiopurines! Examples: azathioprine (Imuran), 6MP (6-mercaptopurine)! Oral! Mechanism of action: immunosuppression- inhibits lymphocytes via inhibition of DNA synthesis! Site of action: systemic! Side effects: nausea, allergic reaction, pancreatitis, bone marrow suppression, drug induced hepatitis, infection, lymphoma, nonmelanomatous skin cancer! Tips: a low dose can help prevent your body from forming antibodies against biologic medications (anti TNF and anti integrin)

12 Methotrexate! Oral or Subcutaneous injection! Mechanism of action: immunosuppressant: inhibits lymphocyte proliferation (folate antagonist)! Site of action: systemic! Side effects: rash, nausea, mucositis, diarrhea, bone marrow suppression, hypersensitivity pneumonitis, elevated liver enzymes/hepatotoxicity, hepatic fibrosis, cirrhosis, must be used with 2 forms of contraception! Tips: take with folic acid 1mg daily and consider taking with an anti nausea medication. No more than 2 drinks per week! Used to treat Crohn s disease and can prevent antibodies against biologics in UC and Crohn s

13 Biologics! Genetically engineered from living organisms! Interfere with the body's inflammatory response by targeting specific molecular players in the process such as cytokines! Examples: Anti TNF (Tumor Necrosis Factor) & Anti Integrin

14 Antibodies! WHAT s an ANTIBODY? An antibody is a protein produced by the body's immune system when it detects foreign substances, called antigens! Antibodies are your bodies becoming immune to the biologic medication- rendering it ineffective and causing side effects! Strategies for preventing antibodies:! Take your medications on time; don t miss doses! For medications given as an infusion, ask your provider about premedications with a steroid, Tylenol, and Benadryl! Ask your doctor about adding a 6MP, azathioprine, or methotrexate

15 Anti-TNFs! Examples: IV: Remicade (infliximab); SubQ injection: Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)! Used in moderate and severe IBD! Mechanism of action: binds and inhibits tumor necrosis factor alpha, reducing inflammation and altering immune response! Site of action: systemic! Side effects: infusion reactions, delayed hypersensitivity reactions, new or worsening heart failure, injection site reactions, autoantibody formation, drug- induced lupus, demyelinating disorders, Non Hodgkins lymphoma, infection (including but not limited to tuberculosis, histoplasmosis, coccidiomycosis, listeriosis)

16 Getting the most out of your anti TNF! anti TNFs are most effective when used in combination with a thiopurine (azathioprine, 6MP)! Know your strategies to prevent antibodies! If your anti TNF isn t working and you still have inflammation in the bowel think of why this and ask your provider about checking a drug level and antibody (Remicade and Humira)! Non responder! Inadequate dose! Antibody formation

17 Which anti TNF should I take?! This decision should be individualized but a few thoughts:! Simponi not approved for Crohn s, Cimzia not FDA approved for UC! Insurance premiums! Convenience of IV vs. SubQ! Ability to check levels and antibody (Remicade, Humira)! Pregnancy consideration (Cimzia)! Severe colitis prefer Remicade

18 Anti Integrin! Examples: Tysabri (natalizumab)- Crohn s, Entyvio (vedolizumab)- UC and Crohn s! Mechanism of action of Entyvio: to block inflammatory cells (lymphocytes) from migrating into the intestine. Tysabri is not gut specific! Site of action: intestine! Side effects: runny nose/sore throat (nasopharyngitis), infection, elevated liver tests! Tips: use strategies to prevent antibodies

19 How long you will need to take the medications! High chance of flaring if stop infliximab (>40% in 1 year)! The answer is never forever. Forever is a long time! Yearly re-evaluation! Re-evaluate goals! Re-evaluate new knowledge on the medications! Are there new medications with better results or less side effects?! Important to not lose a medication that works! Starting and stopping could make the medication less likely to work

20 What can I eat?! If there is a narrowing or blockage in the bowel: use a low residue diet (avoiding roughage and foods high in fiber)! Many fad diets and other diets have anecdotal evidence! To date, Western medicine does not support any particular dietary modification for IBD.! Food in general is mildly irritating to Crohn s disease! IV nutrition or elemental diets are better for Crohn s but are not practical! Exclusion diets have not yielded any specific exclusion diet that is helpful.! Bottom line: Unless you have a blockage, eat a healthy balanced diet that doesn t cause pain and avoid what does cause pain! Important not to restrict calories when the disease is active

21 Complementary and Alternative Medicines (CAM)! A group of diverse medical and healthcare systems, practices, and products that are not presently considered part of conventional medicine

22 Complementary and Alternative Medicines (CAM)! Mind-Body Medicine, Manipulative and Body-Based Practices, Energy Medicine! Biologically-Based Practices- many are not FDA approved! Although dietary supplement manufacturers must register their facilities with FDA,* they are not required to get FDA approval before producing or selling dietary supplements! Vitamins! Supplements! Probiotics!

23 Probiotics! Probiotics are live bacteria that are used to restore the balance of these good bacteria in the body.! Available in the form of dietary supplements (capsules, tablets, and powders) or foods! Little evidence to support use in Crohn s disease! Evidence supports the use of VSL#3 in ulcerative colitis and pouchitis- helps with symptoms, not sure if it helps with healing! Taking probiotics is generally safe

24 Fish Oils! Omega-3 fatty acids found in fatty fish such as salmon, mackerel, herring, and sardines as well as some nuts and green vegetables provide an anti-inflammatory effect! It has been suggested that they may also help to relieve the intestinal inflammation of Crohn s disease and ulcerative colitis! Several studies evaluating omega-3 fatty acids have yielded conflicting findings.! I do not recommend it based on current research

25 Other interesting CAM! Aloe vera gel! Boswellia! Bromelain! Curcumin! Ginger

26 Bottom line on CAMs.! Just because it is natural does not mean it is safe! Some herbals can actually worsen IBD symptoms! Discuss CAM with your provider! Would consider CAM as supplementary rather than the only therapy

27 Multiple choice! Which of the following was originally extracted from willow bark! A) mesalamine! B) prednisone! C) omega 3! D) Boswellia

28 Multiple choice! Which of the following was originally extracted from willow bark! A) mesalamine! B) prednisone! C) omega 3! D) Boswellia

29 How to treat the pain! Step #1: identify the cause of the pain: not all pain is IBD related! Step #2: Treat the underlying cause! Intestinal inflammation?! Blockage?! Medication side effect?! Step #3: If medication for IBD isn t working and the pain is ongoing, assess why the medicine isn t working, consider switching the medication, consider surgery

30 How to treat the pain! Non steroidal anti-inflammatories (NSAID)s: can trigger a flare (Ibuprofen, Motrin, Aleve, Naprosyn, Mobic)! If must be used, consider COX-2 selective inhibition (celecoxib/celebrex)! Narcotics: Associated with increased rates of infection and death in outpatients with Crohn s disease, could cause a dilated colon! Acetaminophen (Tylenol) at certain doses, tramadol OK! Anti spasmodics (Levsin, Bentyl)

31 Take Home Points! Stay in communication with your provider to formulate a treatment plan that is best for you! Stick to the plan, or discuss changes with your provider! There are always treatment options; there is always hope

32 Thank you! Questions?

Top 10 Things you need to know about IBD. Suresh Pola, MD Kaiser San Diego

Top 10 Things you need to know about IBD. Suresh Pola, MD Kaiser San Diego Top 10 Things you need to know about IBD Suresh Pola, MD Kaiser San Diego Top 10 Things to Know: IBD What you can eat How to treat the pain Not all diarrhea is a flare Ways to reduce your risk of getting

More information

Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor

Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor Garrick Brown, MD Digestive Health Specialists Tacoma Gig Harbor Today s Objectives Define IBD, its potential causes and diagnosis Discuss management and treatment Discuss complementary and alternative

More information

I B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES

I B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES I B D m etter than this isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES What types of people have learned how to manage their IBD? Athletes Musicians Firefighters DOCTORS HEROES Artists Presidents Actors

More information

Outline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF

Outline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic

More information

Understanding Inflammatory Bowel Diseases (IBD):

Understanding Inflammatory Bowel Diseases (IBD): Understanding Inflammatory Bowel Diseases (IBD): What Every Patient Needs to Know William H Holderman, MD Digestive Health Specialists Tacoma, WA Today s Objectives Define IBD, its potential causes and

More information

Medical therapies and IBD

Medical therapies and IBD Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,

More information

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight

More information

Understanding IBD Medications and Side Effects

Understanding IBD Medications and Side Effects Understanding IBD Medications and Side Effects a What s Inside About Crohn s Disease and Ulcerative Colitis... 2 Over-the-Counter (OTC) Medications... 5 Prescription Medications... 6 Off-Label... 9 Complementary

More information

10/23/2014. Program Goals

10/23/2014. Program Goals Program Goals Help you understand ulcerative colitis and its effects Review current treatments, including medications, and surgery Provide tips for managing your disease through diet and complementary

More information

IBD Module 2: Medication and Patient Management. Kami Roake, PharmD Rheumatology & Gastroenterology Pharmacist University of Utah Hospitals & Clinics

IBD Module 2: Medication and Patient Management. Kami Roake, PharmD Rheumatology & Gastroenterology Pharmacist University of Utah Hospitals & Clinics IBD Module 2: Medication and Patient Management Kami Roake, PharmD Rheumatology & Gastroenterology Pharmacist University of Utah Hospitals & Clinics Objectives Describe current treatment guidelines and

More information

This program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda

This program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda This program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda Today s Presenter Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,

More information

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation

More information

Of Treatment For Inflammatory Bowel Diseases

Of Treatment For Inflammatory Bowel Diseases Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock

More information

Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group.

Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group. Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online. Last week s material consisted of an overview of inflammatory bowel diseases (IBD), specifically Crohn s disease and ulcerative

More information

Medical Therapy for Pediatric IBD: Efficacy and Safety

Medical Therapy for Pediatric IBD: Efficacy and Safety Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission

More information

The Medical Letter. on Drugs and Therapeutics. Sulfasalazine can cause reversible. therapy may be more effective Lialda (Shire)

The Medical Letter. on Drugs and Therapeutics. Sulfasalazine can cause reversible. therapy may be more effective Lialda (Shire) The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13 Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship

More information

Inflammatory Bowel Diseases

Inflammatory Bowel Diseases Objectives Today s discussion will address the following topics: Similarities and differences between Crohn s disease (CD) and ulcerative colitis (UC) Risks and benefits of medication, surgery, and integrative

More information

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,

More information

INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments

INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments Phillip Minar, MD Pediatric Gastroenterologist Cincinnati Children s Hospital Medical Center Objectives of Session What

More information

This program is supported by an educational grant from Janssen Biotech Inc, and a sponsorship from Takeda.

This program is supported by an educational grant from Janssen Biotech Inc, and a sponsorship from Takeda. This program is supported by an educational grant from Janssen Biotech Inc, and a sponsorship from Takeda. Objectives Today s discussion will address the following topics: Similarities and differences

More information

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

My Child Has Inflammatory Bowel Disease : Why? What now? What s next? My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology

More information

Carefirst.+.V Family of health care plans

Carefirst.+.V Family of health care plans Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific

More information

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest) EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions

More information

Pharmacotherapy of Inflammatory Bowel Disorder

Pharmacotherapy of Inflammatory Bowel Disorder PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523

More information

What Will This Talk Cover? 101: The Basics of Inflammatory Bowel Disease. Terms & Abbreviations. What Is Normal GI Anatomy?

What Will This Talk Cover? 101: The Basics of Inflammatory Bowel Disease. Terms & Abbreviations. What Is Normal GI Anatomy? 101: The Basics of Inflammatory Bowel Disease What Will This Talk Cover? What is IBD? What causes it? What are complications of it? How do I find out if I have IBD? How do we treat IBD? Jennifer Choi,

More information

PEDIATRIC INFLAMMATORY BOWEL DISEASE

PEDIATRIC INFLAMMATORY BOWEL DISEASE PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease

More information

Treating Crohn s and Colitis in the ASC

Treating Crohn s and Colitis in the ASC Treating Crohn s and Colitis in the ASC Kimberly M Persley, MD Texas Digestive Disease consultants TASC Meeting Outline IBD 101 Diagnosis Treatment Burden of Disease Role of ASC Inflammatory Bowel Disease

More information

INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments

INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments Phillip Minar, MD, MS Pediatric Gastroenterologist Cincinnati Children s Hospital Medical Center 3.3.2019 Objectives

More information

Inflammatory Bowel Disease

Inflammatory Bowel Disease Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. Crohn's disease andulcerative colitis are the principal types of inflammatory

More information

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease Mark Lazarev, MD Summary Inflammatory bowel disease (IBD) is a complex disease that is costly both in terms of medical costs

More information

Speaker Introduction

Speaker Introduction Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine

More information

Pharmacotherapy of Inflammatory Bowel Disorder

Pharmacotherapy of Inflammatory Bowel Disorder PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523

More information

Crohn's Disease. What causes Crohn s disease? What are the symptoms?

Crohn's Disease. What causes Crohn s disease? What are the symptoms? Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI

More information

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly

More information

IBD Medical Treatments 2018

IBD Medical Treatments 2018 Specialty Medicine with Commitment, Care and Compassion IBD Medical Treatments 2018 Swapna B. Reddy, M.D. TOC GI South October 6, 2018 10/10/2018 CCF Best Practices in IBD Management 1 Goals of Treatment

More information

We will discuss: Inflammatory Bowel Diseases. Life With IBD. What Are the Potential Causes of IBD?

We will discuss: Inflammatory Bowel Diseases. Life With IBD. What Are the Potential Causes of IBD? We will discuss: Similarities and differences between Crohn s disease (CD) and ulcerative colitis (UC) Risks and benefits of medication, surgery, and integrative treatments in inflammatory bowel diseases

More information

Understanding IBD Medications. and Side Effects

Understanding IBD Medications. and Side Effects Understanding IBD Medications and Side Effects What s Inside? About Crohn s Disease and Ulcerative Colitis 2 Treatment 4 Over-the-Counter (OTC) Medications 5 Prescription Medications 6 Off-Label 8 Pediatric

More information

INFLAMMATORY BOWEL DISEASE. Brittany Palasik, PharmD, BCPS University of North Texas System College of Pharmacy

INFLAMMATORY BOWEL DISEASE. Brittany Palasik, PharmD, BCPS University of North Texas System College of Pharmacy INFLAMMATORY BOWEL DISEASE Brittany Palasik, PharmD, BCPS University of North Texas System College of Pharmacy Pharmacist learning objectives By the end of this presentation, the pharmacist should be able

More information

Addressing Risks and Benefits In IBD

Addressing Risks and Benefits In IBD Addressing Risks and Benefits In IBD Gil Y. Melmed, MD, MS Assistant Professor of Medicine, Cedars-Sinai Medical Center David Geffen School of Medicine at UCLA www.nomorecrohnsdisease.com "Jaw Dropping

More information

WHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? INDICATIONS IMPORTANT RISK INFORMATION

WHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? INDICATIONS IMPORTANT RISK INFORMATION WHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? Learn how DELZICOL can help you manage your ulcerative colitis INDICATIONS DELZICOL (mesalamine) delayed-release capsules is a prescription medication

More information

Understanding Inflammatory Bowel Diseases: What Every Patient Needs to Know

Understanding Inflammatory Bowel Diseases: What Every Patient Needs to Know Understanding Inflammatory Bowel Diseases: What Every Patient Needs to Know An educational program for patients, families and caregivers living with Crohn s disease and ulcerative colitis. Dr. William

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 131 Effective Health Care Program Pharmacologic Therapies for the Management of Crohn s Disease: Comparative Effectiveness Executive Summary Description of Crohn

More information

The ABCs of Inflammatory Bowel Disease. Jennifer Choi, M.D. Associate Director March 31, 2012

The ABCs of Inflammatory Bowel Disease. Jennifer Choi, M.D. Associate Director March 31, 2012 The ABCs of Inflammatory Bowel Disease Jennifer Choi, M.D. Associate Director March 31, 2012 What Will This Talk Cover? What is IBD? What causes it? What are complications of it? How do I find out if I

More information

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.

More information

Understanding Your Benefits and Risks

Understanding Your Benefits and Risks IBD Treatment Options Understanding Your Benefits and Risks benefit risk assessment tool Understand your options. Improve your health... and life. Inflammatory bowel disease (IBD) is two, separate disorders

More information

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence

More information

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I

More information

Inflammatory Bowel Disease Medical Exam Questionnaire

Inflammatory Bowel Disease Medical Exam Questionnaire Patient Name: MR: Date: Name DOB / / Age Marital Status Race Gender M / F Height Present Weight Usual Weight Insurance Managed Care Self referral Yes No Yes No Yes No Primary Care Physician Referring Physician

More information

Improving outcome of Inflammatory Bowel Disease in children

Improving outcome of Inflammatory Bowel Disease in children Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University School of Medicine Pediatric Gastroenterology

More information

NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL

NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural

More information

The London Gastroenterology Partnership CROHN S DISEASE

The London Gastroenterology Partnership CROHN S DISEASE CROHN S DISEASE What is Crohn s disease? Crohn s disease is a condition, in which inflammation develops in parts of the gut leading to symptoms such as diarrhoea, abdominal pain and tiredness. The inflammation

More information

62 HUMIRA (ADALIMUMAB) 62 Forecast assumptions 66 Humira forecast Bibliography 70 LIALDA (MESALAZINE MMX) 71 Lialda forecast

62 HUMIRA (ADALIMUMAB) 62 Forecast assumptions 66 Humira forecast Bibliography 70 LIALDA (MESALAZINE MMX) 71 Lialda forecast TABLE OF CONTENTS To request sample pages please contact us at getcloser@datamonitorhealthcare.com 8 EXECUTIVE SUMMARY 9 METHODOLOGY AND MARKET DEFINITION 9 Market definition for inflammatory bowel disease

More information

The Road to Remission

The Road to Remission The Road to Remission Understanding, Treating and Living with Inflammatory Bowel Disease IBDCenterOrlando.com As many as 1.5 million Americans currently suffer from inflammatory bowel disease (IBD), and

More information

Pharmacotherapy of Inflammatory Bowel Disorder

Pharmacotherapy of Inflammatory Bowel Disorder PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523

More information

Certain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.

Certain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs. Topic Page: Crohn's disease Definition: Crohn's disease from Benders' Dictionary of Nutrition and Food Technology Chronic inflammatory disease of the bowel, commonly the terminal ileum, of unknown aetiology,

More information

o Your healthcare provider should test you for TB before starting CIMZIA.

o Your healthcare provider should test you for TB before starting CIMZIA. Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each

More information

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease Mark Lazarev, MD November 14, 2013 Assistant Professor of Medicine, Johns Hopkins University School of Medicine Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease 1 Talk outline

More information

Clinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07.16 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits. Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically

More information

MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)

MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

More information

INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE

INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE Symptoms The symptoms of Crohn s disease can vary from person to person, based on where the disease is in the body and how bad the inflammation is. The

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

INFLAMMATORY BOWEL DISEASE 101: Understanding Your Child s Diagnosis

INFLAMMATORY BOWEL DISEASE 101: Understanding Your Child s Diagnosis INFLAMMATORY BOWEL DISEASE 101: Understanding Your Child s Diagnosis Phillip Minar, MD Pediatric Gastroenterologist Cincinnati Children s Hospital Medical Center Objectives What is IBD Crohn s disease

More information

What is Crohn's disease?

What is Crohn's disease? What is Crohn's disease? Crohn's disease is a chronic inflammatory disorder that causes inflammation of the digestive tract. It can affect any area of the GI tract, from the mouth to the anus, but it most

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Tysabri (natalizumab) MP-042-MD-WV Provider Notice Date: 10/01/2017 Original Effective Date: 11/01/2017 Annual Approval Date:

More information

Crohn s Disease. Resident Lecture 1/17/19

Crohn s Disease. Resident Lecture 1/17/19 Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with

More information

Practical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center

Practical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center Practical Risk Management Tools for Patients with IBD Garth Swanson MD Rush University Medical Center IBD Therapy Severity Tysabri Surgery Infliximab, i Adalimumab, Certilizumab Corticosteroids, Immunomodulators

More information

vedolizumab (Entyvio )

vedolizumab (Entyvio ) vedolizumab (Entyvio ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ),

More information

Evidence review for Surrey Prescribing Clinical Network SUMMARY

Evidence review for Surrey Prescribing Clinical Network SUMMARY East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine

More information

COPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease

COPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and

More information

Pediatric Inflammatory Bowel Diseases

Pediatric Inflammatory Bowel Diseases Pediatric Inflammatory Bowel Diseases Michael Stephens, M.D. Denny Sanford Pediatric Symposium November 21 2014, Sioux Falls, SD 2014 slide-1 Disclosures I have nothing to disclose 2014 slide-2 Objectives

More information

Slide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology

Slide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology Slide 1 Medications in inflammatory bowel disease a primer for health care providers Athos Bousvaros, MD Associate director Inflammatory Bowel Disease Center Boston Children s Hospital 617 355 2962 Slide

More information

Managing. Inflammatory Bowel Disease. Slide 1. Slide 2. Slide 3. Disclosures. Vijay Yajnik, MD., PhD 01/25/14. None relevant to this talk

Managing. Inflammatory Bowel Disease. Slide 1. Slide 2. Slide 3. Disclosures. Vijay Yajnik, MD., PhD 01/25/14. None relevant to this talk Slide 1 Managing Inflammatory Bowel Disease Vijay Yajnik, MD., PhD 01/25/14 Slide 2 Disclosures None relevant to this talk 2 Slide 3 Inflammatory Bowel Disease Topics Covered My friend called me and she

More information

Ali Keshavarzian MD Rush University Medical Center

Ali Keshavarzian MD Rush University Medical Center Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting

More information

New Perspectives on the Diagnosis and Management of IBD. Disclosures

New Perspectives on the Diagnosis and Management of IBD. Disclosures New Perspectives on the Diagnosis and Management of IBD Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children's Hospital/Atlantic Health Professor of Pediatrics Icahn School of Medicine

More information

ENTYVIO (VEDOLIZUMAB)

ENTYVIO (VEDOLIZUMAB) ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...

More information

Psoriatic Arthritis- Second Line Treatments

Psoriatic Arthritis- Second Line Treatments Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist

More information

UNDERSTANDING CROHN S DISEASE

UNDERSTANDING CROHN S DISEASE UNDERSTANDING CROHN S DISEASE START YOUR JOURNEY TOWARD UNDERSTANDING INFLAMMATORY BOWEL DISEASE CONTENTS INTRODUCTION 4 WHAT IS CROHN S DISEASE? 6 Symptoms of Crohn s disease 6 WHAT CAUSES CROHN S DISEASE?

More information

Medications. A: Specific medications

Medications. A: Specific medications Medications This section describes the medications used in IBD, how they work, when they are used and their more common and important side-effects. The list of side-effects is not all inclusive. If you

More information

Moderately to severely active ulcerative colitis

Moderately to severely active ulcerative colitis Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients

More information

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University

More information

This information explains the advice about Crohn's disease that is set out in NICE guideline CG152.

This information explains the advice about Crohn's disease that is set out in NICE guideline CG152. Information for the public Published: 1 October 2012 nice.org.uk About this information NICE guidelines provide advice on the care and support that should be offered to people who use health and care services.

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:

More information

What is Inflammatory Bowel Disease (IBD)?

What is Inflammatory Bowel Disease (IBD)? INFLAMMATORY BOWEL DISEASE (IBD) What is Inflammatory Bowel Disease (IBD)? Inflammatory bowel disease, or IBD, is when there is inflammation, or swelling, in the gastrointestinal (GI) tract and a lifelong

More information

Welcome to Juvenile Rheumatoid Arthritis or JRA, by Connie Martin, MS, RDN; Claire Stephens, MS, RDN; and Lolita McLean, MPH, RDN...

Welcome to Juvenile Rheumatoid Arthritis or JRA, by Connie Martin, MS, RDN; Claire Stephens, MS, RDN; and Lolita McLean, MPH, RDN... Welcome to Juvenile Rheumatoid Arthritis or JRA, by Connie Martin, MS, RDN; Claire Stephens, MS, RDN; and Lolita McLean, MPH, RDN...all of Alabama s Children s Rehabilitation Service, part of the Alabama

More information

P a g e 1. Inflammatory Bowel Disease Guidelines

P a g e 1. Inflammatory Bowel Disease Guidelines P a g e 1 Inflammatory Bowel Disease Guidelines Introduction Inflammatory bowel disease (IBD) is a chronic inflammatory disease affecting the gastrointestinal (GI) system. It is comprised of two major

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

Psoriatic Arthritis- Secondary Care

Psoriatic Arthritis- Secondary Care Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the

More information

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic

More information

Complementary & Alternative Therapies in IBD

Complementary & Alternative Therapies in IBD Complementary & Alternative Therapies in IBD Laurie Rosales, APRN-CNP OSU Wexner Medical Center Division of Gastroenterology, Hepatology and Nutrition Complementary & Alternative Probiotics Cannabis Fish

More information

CROHN S DISEASE AND ULCERATIVE COLITIS

CROHN S DISEASE AND ULCERATIVE COLITIS Slide 1 CROHN S DISEASE AND ULCERATIVE COLITIS Slide 2 Slide 3 Crohn s Inflammation in the GI tract but usually in the lower part of the small intestines and the colon. Inflammation occur between healthy

More information

Indications for use of Infliximab

Indications for use of Infliximab Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of

More information

ENTYVIO (vedolizumab)

ENTYVIO (vedolizumab) ENTYVIO (vedolizumab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline

More information